Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study

Peter F Buckley; Nina R Schooler; Donald C Goff; Alex Kopelowicz; John Lauriello; Theo C Manschreck; Alan Mendelowitz; Del D Miller; Daniel R Wilson; Donna Ames; Juan R Bustillo; John M Kane; Stephen W Looney

doi:10.1176/appi.ps.201500466

Back

Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study

Journal article

Open access

Peer reviewed

Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study

Peter F Buckley, Nina R Schooler, Donald C Goff, Alex Kopelowicz, John Lauriello, Theo C Manschreck, Alan Mendelowitz, Del D Miller, Daniel R Wilson, Donna Ames, …

Psychiatric services (Washington, D.C.), Vol.67(12), pp.1370-1372

12/01/2016

DOI: 10.1176/appi.ps.201500466

PMID: 27476806

Files and links (1)

url

https://doi.org/10.1176/appi.ps.201500466View

Published (Version of record) Open Access

Abstract

In a pragmatic clinical trial, this study sought to compare relapses among patients receiving either long-acting injectable or oral second-generation antipsychotics. PROACTIVE (Preventing Relapse Oral Antipsychotics Compared to Injectables Evaluating Efficacy), a prior 30-month relapse prevention study, compared use of a long-acting injectable second-generation antipsychotic with use of an oral second-generation antipsychotic by 305 patients with schizophrenia or schizoaffective disorder and found similar rates of first relapse between groups (42% with injectable medication, 32% with oral medication). This study examined subsequent relapses among patients who had relapsed in PROACTIVE and who continued in treatment, follow-up, or both. Thirty-two patients (11%) experienced two relapses, and 13 patients (4%) had three relapses. Neither rate of relapse nor time to successive relapses differed between treatment groups. There was an impressively low rate of subsequent relapses in this pragmatic clinical trial. Because all patients had a clinic visit according to the biweekly long-acting injectable medication administration schedule, frequent contact may have contributed to low relapse rates. Maintaining frequent clinical contact may be a valid psychosocial relapse prevention treatment.

Administration, Oral

Adult

Antipsychotic Agents - administration & dosage

Antipsychotic Agents - adverse effects

Delayed-Action Preparations

Female

Humans

Injections

Male

Patient Readmission - statistics & numerical data

Psychotic Disorders - drug therapy

Recurrence

Risperidone - administration & dosage

Risperidone - adverse effects

Schizophrenia - drug therapy

Treatment Outcome

United States

Details

Title: Subtitle: Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study
Creators: Peter F Buckley - University of Iowa
Nina R Schooler - SUNY Downstate Health Sciences University
Donald C Goff - New York University
Alex Kopelowicz - University of California at Los Angeles
John Lauriello - University of Missouri
Theo C Manschreck - Harvard University
Alan Mendelowitz - University of Iowa
Del D Miller - University of Iowa
Daniel R Wilson - University of Florida Health Science Center
Donna Ames - University of California, Los Angeles
Juan R Bustillo - University of New Mexico
John M Kane - Zucker Hillside Hospital
Stephen W Looney - Biostats (United States)
Resource Type: Journal article
Publication Details: Psychiatric services (Washington, D.C.), Vol.67(12), pp.1370-1372
DOI: 10.1176/appi.ps.201500466
PMID: 27476806
NLM abbreviation: Psychiatr Serv
ISSN: 1075-2730
eISSN: 1557-9700
Language: English
Date published: 12/01/2016
Academic Unit: Psychiatry
Record Identifier: 9984280869802771

Metrics

19 Record Views

6 Times Cited - Web of Science

See more details